Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Revvity Inc (RVTY) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Revvity Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.8, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Revvity Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPIRVTY
Sector
Income / Options OverlayTechnology
52-Week High
$49.54$117.75
52-Week Low
$37.98$82.26
Market Cap
$12.91B
Enterprise Value
$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.80, showing slight daily weakness with a 0.17% decline. The ETF maintains a bullish technical signal with strong moving average support and weekly dividend distributions averaging $0.20-0.21. Recent news highlights FEPI's aggressive covered call strategy targeting AI and mega-cap tech names to generate its 25% yield, though analysts caution about NAV erosion risks during market downturns.

The outlook remains cautiously optimistic given the bullish technical setup and high income generation, but investors face significant risk from the concentrated tech portfolio and covered call strategy that limits upside potential. Market sentiment is divided between yield-seeking investors and those concerned about long-term NAV preservation in volatile market conditions.

Revvity Inc

RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.

The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY